Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

DNA replication inhibitor

DRUG CLASS:

DNA replication inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	rituximab + acalabrutinib + bendamustine Sensitive: A1 - Approval rituximab + acalabrutinib + bendamustine Sensitive : A1	rituximab + acalabrutinib + bendamustine Sensitive: A1 - Approval rituximab + acalabrutinib + bendamustine Sensitive : A1
CD33 positive	Acute Myelogenous Leukemia	CD33 positive	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: A1 - Approval gemtuzumab ozogamicin Sensitive : A1	gemtuzumab ozogamicin Sensitive: A1 - Approval gemtuzumab ozogamicin Sensitive : A1
CD22 positive	B Acute Lymphoblastic Leukemia	CD22 positive	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	loncastuximab tesirine-lpyl Sensitive: A1 - Approval loncastuximab tesirine-lpyl Sensitive : A1	loncastuximab tesirine-lpyl Sensitive: A1 - Approval loncastuximab tesirine-lpyl Sensitive : A1
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	bendamustine Sensitive: A1 - Approval bendamustine Sensitive : A1	bendamustine Sensitive: A1 - Approval bendamustine Sensitive : A1
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	bendamustine Sensitive: A1 - Approval bendamustine Sensitive : A1	bendamustine Sensitive: A1 - Approval bendamustine Sensitive : A1
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2